DUBLIN--(BUSINESS WIRE)--The "Global Age-Related Macular Degeneration Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering.
The Global Age-Related Macular Degeneration Market is expected to reach $15,882.7 million by 2026 growing at a CAGR of 9.5% from 2018 to 2026.
Some of the factors such as increasing geriatric population and rising predominance of age-related macular degeneration are fuelling the market growth. However, increasing use of off label drugs and availability of off label therapies are restraining the market growth.
Based on the drug, lucentis segment has witnessed significant growth. Lucentis is used to treat the "wet form" of age-related macular degeneration. Lucentis is also used to treat swelling in the retina caused by diabetes or by a blockage in the blood vessels.
The key vendors mentioned are Valeant Pharmaceuticals International, Inc., Stemcells Inc., Santen Pharmaceuticals, Regeneron Pharmaceuticals, Pfizer, Inc., Ophthotech Corporation, Novartis Ag, Neurotech Pharmaceuticals, Inc., Kubota Pharmaceutical Holdings Co. Ltd, GlaxoSmithKline Plc, F. Hoffmann-La Roche, Bayer Healthcare, Alimera Sciences, Inc., Adverum Biotechnologies, Inc., and Acucela.
Key Questions Answered in this Report
- How this market evolved since the year 2016
- Market size estimations, forecasts and CAGR for all the segments presented in the scope
- Key Market Developments and financials of the key players
- Opportunity Analysis for the new entrants
- SWOT Analysis of the key players
- Fastest growing markets analyzed during the forecast period
Key Topics Covered
1 Market Synopsis
2 Research Outline
3 Market Dynamics
3.1 Drivers
3.2 Restraints
4 Market Environment
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Age-Related Macular Degeneration Market, By Drug
5.1 Introduction
5.2 Visudyne
5.3 Lucentis
5.4 Eylea
5.5 Avastin
5.6 Other Drugs
6 Global Age-Related Macular Degeneration Market, By Type
6.1 Introduction
6.2 Dry
6.3 Wet
7 Global Age-Related Macular Degeneration Market, By Stages
7.1 Introduction
7.2 Intermediate
7.3 Early-Stage
7.4 Late Stage
8 Global Age-Related Macular Degeneration Market, By Age group
8.1 Introduction
8.2 Above 75 years
8.3 Above 60 years
8.4 Above 40 years
9 Global Age-Related Macular Degeneration Market, By Route of Administration
9.1 Introduction
9.2 Intravitreal
9.3 Intravenous
10 Global Age-Related Macular Degeneration Market, By Mode of Treatment
10.1 Introduction
10.2 Surgery
10.3 Medication
10.4 Diagnosis
10.5 Devices
11 Global Age-Related Macular Degeneration Market, By Application
11.1 Introduction
11.2 Woman
11.3 Men
12 Global Age-Related Macular Degeneration Market, By End User
12.1 Introduction
12.2 Hospital & Clinics
12.3 Diagnostic Centers
12.4 Biotechnology Companies and Pharmaceuticals
12.5 Academic Research Institutes
13 Global Age-Related Macular Degeneration Market, By Geography
13.1 Introduction
13.2 North America
13.3 Europe
13.4 Asia-Pacific
13.5 South America
13.6 Middle East & Africa
14 Strategic Benchmarking
15 Vendors Landscape
15.1 Valeant Pharmaceuticals International, Inc.
15.2 Stemcells Inc.
15.3 Santen Pharmaceuticals
15.4 Regeneron Pharmaceuticals
15.5 Pfizer, Inc.
15.6 Ophthotech Corporation
15.7 Novartis AG
15.8 Neurotech Pharmaceuticals, Inc.
15.9 Kubota Pharmaceutical Holdings Co. Ltd.
15.10 Glaxosmithkline PLC
15.11 F. Hoffmann-La Roche
15.12 Bayer Healthcare
15.13 Alimera Sciences, Inc.
15.14 Adverum Biotechnologies, Inc.
15.15 Acucela
For more information about this report visit https://www.researchandmarkets.com/r/cvhmxs
